Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation

Simon Gates,1* Ranjit Lall,1 Tom Quinn,2 Charles D Deakin,3 Matthew W Cooke,1,4 Jessica Horton,1 Sarah E Lamb,1,5 Anne-Marie Slowther,1 Malcolm Woollard,2 Andy Carson,6 Mike Smyth,1,6 Kate Wilson,6 Garry Parcell,6 Andrew Rosser,6 Richard Whitfield,7 Amanda Williams,7 Rebecca Jones,7 Helen Pocock,3 Nicola Brock,3 John JM Black,3 John Wright,8,9 Kyee Han,8 Gary Shaw,8 Laura Blair,8 Joachim Marti,10 Claire Hulme,10 Christopher McCabe,11 Silviya Nikolova,10 Zenia Ferreira10 and Gavin D Perkins1,4

1Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
2Surrey Peri-operative Anaesthesia Critical Care Collaborative Research Group, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK (current address: Faculty of Health, Social Care and Education, Kingston University London and St George’s, University of London, London, UK)
3South Central Ambulance Service NHS Foundation Trust, Otterbourne, UK
4Heart of England NHS Foundation Trust, Birmingham, UK
5Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK
6West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, UK
7Welsh Ambulance Services NHS Trust, St Asaph, UK
8North East Ambulance Service NHS Foundation Trust, Newcastle upon Tyne, UK
9Royal Victoria Infirmary, Newcastle upon Tyne, UK
10Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
11Department of Emergency Medicine Research, University of Alberta, Edmonton, AB, Canada

*Corresponding author
Declared competing interests of authors: Simon Gates was a member of the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation Board until February 2015 and the NIHR Standing Advisory Committee on Clinical Trials Units until December 2014 and is a member of the Medical Research Council Methodology Research Programme Panel. Sarah E Lamb is chairperson of the NIHR Health Technology Assessment Clinical Evaluation and Trials Board and member and chairperson of the NIHR Clinical Trials Unit Standing Advisory Committee. Gavin D Perkins is a member of the NIHR Health Services and Delivery Research Researcher-led Panel and is a NIHR Senior Investigator. Claire Hulme is a member of the HTA Commissioning Board.

Published March 2017
DOI: 10.3310/hta21110

Scientific summary

Mechanical chest compression for out-of-hospital cardiac arrest
Health Technology Assessment 2017; Vol. 21: No. 11
DOI: 10.3310/hta21110

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Chest compression is one of the crucial components of cardiopulmonary resuscitation (CPR). However, it is known that it is difficult to maintain adequate depth and frequency of compressions, reducing the patient’s chances of survival. Mechanical chest compression devices have been proposed as a potential solution, as they can provide compressions of standard depth and frequency indefinitely, do not tire and can be used in situations in which manual chest compression is difficult. In this trial we evaluated use of the LUCAS-2 device (Lund University Cardiopulmonary Assistance System-2; Jolife AB, Lund, Sweden), which was introduced into UK ambulance services several years ago without any evidence of effectiveness.

Objectives

1. To conduct a pragmatic, cluster randomised trial of the LUCAS-2 device compared with standard manual chest compression for patients experiencing an out-of-hospital cardiac arrest.
2. To conduct an economic evaluation to estimate the cost-effectiveness of the LUCAS-2 device.
3. To perform a systematic review to combine the results of the current trial with those of other recent trials of mechanical chest compression.

Methods

Study design

The design was a cluster randomised controlled trial (RCT), with ambulance service vehicles [ambulances and rapid response vehicles (RRVs)] as the units of randomisation. Four UK ambulance services took part. An economic evaluation was also conducted and we performed a systematic review to synthesise the results of this and other recent randomised trials of mechanical chest compression.

Outcomes

Primary

1. Survival to 30 days post cardiac arrest.

Secondary

1. Survived event (survival to hospital).
2. Survival to hospital discharge.
3. Survival to 3 and 12 months.
4. Health-related quality of life at 3 and 12 months [Short Form questionnaire-12 items (SF-12)].
5. Neurological outcome at discharge from hospital [as measured via the Cerebral Performance Category (CPC) scale with a score of 1 or 2 vs. 3–5].
6. Neurological outcome at 12 months (as measured via the Mini Mental State Examination).
7. Anxiety and depression at 12 months (as measured via the Hospital Anxiety and Depression Scale).
8. Post-traumatic stress at 12 months (as measured via the Post-Traumatic Stress Disorder Civilian Checklist).
9. Hospital length of stay.
10. Intensive care length of stay.
**Inclusion criteria**
Patients were included if they were in cardiac arrest, if they were out of hospital, if resuscitation was attempted and if they were attended by a trial vehicle. Exclusions were cardiac arrest due to trauma, patients with a known or clinically apparent pregnancy and patients known to be or apparently aged < 18 years.

**Randomisation and treatment**
Cardiac arrests were identified from routine ambulance service records. Patients were automatically included in the trial if they met the inclusion criteria.

**Data collection**
Data were collected by research paramedics from ambulance service records. Deaths were identified from ambulance services and routine UK NHS data via the Health and Social Care Information Centre. Surviving patients were contacted for consent for follow-up and, if consent was given, they were visited at 3 and 12 months post cardiac arrest.

**Analysis**
We performed an intention-to-treat (ITT) analysis and, because of lower-than-expected compliance in the LUCAS-2 arm, complier average causal effect (CACE) analyses. For the CACE analyses, we classified cases of non-compliance into those that would happen in normal clinical practice (e.g. device malfunction, location too restricted to use the LUCAS-2 device) and those that were specific to the context of the trial.

**Economic evaluation**
The economic evaluation assessed the cost-effectiveness of use of the LUCAS-2 device. It consisted of two complementary sets of analyses: a within-trial analysis over the 12-month trial period and a decision-analytic model that was constructed to extrapolate the results over the expected lifetime of the trial participants. The cost-effectiveness analyses were conducted from the NHS and Personal Social Services perspective. The analyses report cost per incremental quality-adjusted life-year of LUCAS-2 compared with usual care (manual chest compression). Data from various sources were combined to estimate costs and treatment benefits, including trial case report forms, large data sets (i.e. Hospital Episode Statistics, Intensive Care National Audit and Research Centre data), self-completed patient questionnaires and data extracted from the literature.

**Systematic review**
We searched for randomised trials evaluating mechanical chest compression (using any device) published since 1990 (search date February 2015). Data were extracted by two authors and meta-analyses conducted using Review Manager software version 5.3 (RevMan, The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Outcomes were return of spontaneous circulation, survival of event, survival to discharge from hospital or 30 days and survival with good neurological outcome (measured by CPC or modified Rankin Scale).

**Results**
We enrolled 4471 eligible patients (1652 assigned to the LUCAS-2 group and 2819 assigned to the control group) between 15 April 2010 and 10 June 2013. Nine hundred and eighty-five (60%) patients in the LUCAS-2 group received mechanical chest compression and 11 (< 1%) patients in the control group received LUCAS-2 treatment. In the ITT analysis, 30-day survival was similar in the LUCAS-2 [104 (6.3%) of 1652 patients] and manual CPR groups [193 (6.8%) of 2819 patients; adjusted odds ratio (OR) 0.86, 95% confidence interval (CI) 0.64 to 1.15]. Survival with a CPC score of 1 or 2 was worse in the LUCAS-2 group (adjusted OR 0.72, 95% CI 0.52 to 0.99). No serious adverse events were noted. The systematic review found no evidence that mechanical chest compression was superior to manual. The economic analysis consistently showed that treatment with the LUCAS-2 device was more costly and less effective than manual CPR, although differences in mean costs and outcomes between both treatment arms were fairly small.
These results were obtained both in the within-trial analysis and in the analysis that modelled lifetime costs and outcomes. When missing data were handled by multiple imputation, estimated costs were higher in both arms, but the incremental cost-effectiveness ratios also indicated that manual CPR dominates LUCAS-2.

**Conclusions**

The trial, systematic review and economic evaluation all found that there was no evidence that mechanical chest compression using LUCAS-2 was superior to standard manual chest compression.

**Trial registration**

This trial is registered as ISRCTN08233942.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed `systematic` when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 07/37/69. The contractual start date was in June 2009. The draft report began editorial review in July 2015 and was accepted for publication in May 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document.

However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gates et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsmma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk